Proceeds used to complete ongoing ATHENA pivotal IDE study, continue product development, and secure global regulatory approvals for neurovascular portfolio
BARCELONA, Spain and MARIN, Calif. – September 23, 2026 – Anaconda Biomed, a medical technology company developing a next-generation portfolio of novel thrombectomy catheters based on its core funnel catheter technology platform, today announced the closing of a $56 million financing round with participation from new and existing investors. Proceeds will support product development and clinical work, including completion of the ongoing ATHENA pivotal IDE study, a prospective, randomized, 327-subject trial intended to evaluate the safety and performance of the ANA Funnel Catheter.